Company news

Starpharma Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Starpharma annual report and full year financial results

August 25, 2022

Starpharma signs new DEP agreement with MSD

August 10, 2022

Quarterly Activities Report & Appendix 4C

July 28, 2022

VIRALEZE Protects Against Omicron in Viral Challenge Model

July 20, 2022

VIRALEZE relaunched by LloydsPharmacy in the UK

June 30, 2022

SPL signs expanded DEP research agreement with US Biopharma

June 26, 2022

SPL7013 in VIRALEZE virucidal against influenza A and B

May 17, 2022

Quarterly Cashflow and Activities Report

April 29, 2022

Quarterly Cashflow and Activities Report

April 28, 2022

VIRALEZE to relaunch in the UK

March 31, 2022

Application for quotation of securities - SPL

March 17, 2022

SPL7013 in VIRALEZE virucidal against Omicron

March 1, 2022

Interim Report and Half-Year Financial Results

February 20, 2022

VIRALEZE sales and distribution in Saudi Arabia and GCC

February 2, 2022

Starpharma - Quarterly Cashflow and Activities Report

January 31, 2022

Starpharma receives $7.7M R&D tax incentive refund

January 19, 2022

VIRALEZE successfully launched in Vietnam

December 13, 2021

Starpharma signs DEP Research Agreement with US Biopharma Co

December 6, 2021

VIRALEZE distribution agreement and launch in Vietnam

December 2, 2021

VIRALEZE registered in Vietnam with launch this week

November 30, 2021

AGM Chairman address and CEO presentation

November 29, 2021

Positive DEP phase 2 interim results in prostate cancer

November 25, 2021

VIRALEZE distribution and supply to Vietnam

October 25, 2021

VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy

October 7, 2021

VIRALEZE Protects Against SARS-CoV-2 in Challenge Model

August 23, 2021

VIRALEZE well tolerated in multiple dose clinical study

August 17, 2021

VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant

July 27, 2021

VIRALEZE UK Update

June 20, 2021

VIRALEZE SPL7013 virucidal against multiple COVID variants

June 17, 2021

VIRALEZE antiviral nasal spray registered for sale in India

June 11, 2021

VIRALEZE SPL7013 highly active in UK variant of coronavirus

June 1, 2021

VIRALEZE launches in Europe

May 6, 2021

VIRALEZE™ now launched by LloydsPharmacy in the UK

March 29, 2021

VIRALEZE to be launched with LloydsPharmacy in the UK

March 24, 2021

DEP HER2-lutetium outperforms in human breast cancer model

March 15, 2021

VIRALEZE antiviral nasal spray registered in Europe

February 22, 2021

Starpharma signs DEP ADC Research Agreement with MSD

February 11, 2021

AZD0466 clinical DEP program global expansion

February 8, 2021

Change in substantial holding

February 2, 2021

VIRALEZE COVID-19 nasal spray study to commence in January

December 22, 2020

VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21

December 9, 2020

SPL7013 shows potent antiviral activity in RSV

November 18, 2020

Completion of Placement and SPP raises $48.9M in total

October 29, 2020

Starpharma receives $5.7M R&D tax incentive refund

October 20, 2020

Share Purchase Plan offer document

October 6, 2020

Starpharma completes oversubscribed A$45M placement

September 30, 2020

SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2

September 14, 2020

Starpharma awarded $1M MRFF funding for COVID-19 spray

September 2, 2020

SPL creates slow release soluble DEP remdesivir nanoparticle

August 31, 2020

SPL7013 nasal spray for COVID19 development update

August 25, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 50 decks. Every deck is listed under its year.